Connect
MJA
MJA

Standing at the crossroads in HIV management: implications for primary care practice from the AIDS 2014 conference

Levinia Crooks, Michael R Kidd, Robert Lake, Edwina J Wright and Edward Reis
Med J Aust 2014; 201 (8): . || doi: 10.5694/mja14.01106
Published online: 20 October 2014

Increase testing, increase treatment, consider prophylaxis, search for a cure and try to eradicate HIV

There has recently been renewed interest in HIV management in Australia. Studies have contributed evidence that effective HIV antiretroviral treatment (ART)1,2 and chemoprophylaxis3 prevent HIV transmission. There is a push to identify people with chronic HIV infection who have not been tested4 and to identify people during the acute phase of infection,5,6 when they are most infectious and most likely to transmit disease7 but unlikely to know they are infected.8 HIV treatment is more effective than it was previously; lower pill burdens cause fewer side effects and less toxicity and are less prone to the development of resistance. When combined with traditional HIV prevention measures, the use of antiretroviral agents as pre-exposure prophylaxis (PrEP) by HIV-negative people at high risk of HIV infection reduces transmission by about 75%. The World Health Organization recently recommended PrEP be integrated into prevention programs.9


  • 1 Australasian Society for HIV Medicine, Sydney, NSW.
  • 2 School of Public Health and Human Biosciences, La Trobe University, Melbourne, VIC.
  • 3 Faculty of Medicine, Nursing and Health Sciences, Flinders University, Adelaide, SA.
  • 4 Australian Federation of AIDS Organisations, Sydney, NSW.
  • 5 The Alfred Hospital, Melbourne, VIC.


Correspondence: Levinia.Crooks@ashm.org.au

Competing interests:

No relevant disclosures.

  • 1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
  • 2. Rodger A, Bruun T, Cambiano V, et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER Study. Abstract 153LB. In: Proceedings of CROI 2014: Conference on Retroviruses and Opportunistic Infections; 2014 Mar 3-6; Boston, Mass, USA. http://croi2014.org/sites/default/files/uploads/CROI2014_Final_Abstracts.pdf (accessed Sep 2014).
  • 3. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS 2012; 7: 99-105.
  • 4. HIV in Europe Secretariat. HIV indicator conditions: guidance for implementing HIV testing in adults in health care settings. http://issuu.com/kandrup/docs/chip_guidance?e=4233206/1998749#222222 (accessed Aug 2014).
  • 5. Australasian Society for HIV Medicine. Testing portal [website]. http://testingportal.ashm.org.au (accessed Aug 2014).
  • 6. Sexually Transmissible Infections in Gay Men Action Group. STI testing guidelines for MSM. Sydney: New South Wales Sexually Transmissible Infections Programs Unit, 2014. http://stipu.nsw.gov.au/stigma/sti-testing-guidelines-for-msm (accessed Aug 2014).
  • 7. Quinn TC, Wawer MJ, Sewankambo N, et al; Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-929.
  • 8. Chibo D, Kaye M, Birch C. HIV transmissions during seroconversion contribute significantly to new infections in men who have sex with men in Australia. AIDS Res Hum Retroviruses 2012; 28: 460-464. doi: 10.1089/aid.2011.0137.
  • 9. World Health Organization. Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV. Geneva: WHO, 2012. http://www.who.int/hiv/pub/guidance_prep/en (accessed Aug 2014).
  • 10. Proceedings of the 20th International AIDS Conference; 2014 Jul 20-25; Melbourne, Australia. http://pag.aids2014.org (accessed Sep 2014).
  • 11. Cairns G. Reappearance of HIV in “Mississippi Baby” poses questions for early treatment. NAM 2014; 22 Jul. http://www.aidsmap.com/Reappearance-of-HIV-in-Mississippi-Baby-poses-questions-for-early-treatment/page/2893308 (accessed Aug 2014).
  • 12. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2014: a clinical practice guideline. Atlanta: Centers for Disease Control and Prevention, 2014. http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf (accessed Sep 2014).
  • 13. Westrop SJ, Hartney T, Gill N, et al. Addressing late HIV diagnosis through screening and testing: an evidence summary. PHE publications gateway number 2014018. London: Public Health England, 2014. http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/hivtesting (accessed Sep 2014).
  • 14. Australasian Society for HIV Medicine. Testing portal: HIV. Informed consent for testing. http://testingportal.ashm.org.au/hiv/informed-consent-for-testing (accessed Aug 2014).
  • 15. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57.
  • 16. Australasian Society for HIV Medicine. Australian Commentary on the US Department of Health and Human Services (DHHS) guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://arv.ashm.org.au (accessed Sep 2014).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.